Why CAMP4?
Leadership
Investors
About Our Name
RAP Platform
Reg Actuators
Programmable Therapeutics
Publications & Presentations
Pipeline
Newsroom
Join the Adventure
Recent News
July 20, 2022
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
Read More
Contact Us
Privacy Policy
Menu
Newsroom
Views and missives from the frontier
All
Press Releases
Perspectives
In the News
Videos
July 20, 2022
Press Releases
CAMP4 Secures $100 Million Series B Financing to Accelerate Expansion of its Novel Regulatory RNA-Targeting Platform and Advance Lead Programs into the Clinic
April 19, 2022
Press Releases
CAMP4 Therapeutics Promotes Kelly Gold to Chief Financial Officer
March 14, 2022
Press Releases
CAMP4 Therapeutics Appoints Veteran Drug Developer Ann Barbier, M.D., Ph.D. as Chief Medical Officer
December 3, 2021
Press Releases
CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
September 27, 2021
Press Releases
CAMP4 Presents First Preclinical Data Demonstrating the Therapeutic Potential of its RNA Actuating Platform at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
July 13, 2021
Press Releases
CAMP4 Therapeutics Expands Leadership and Board of Directors
June 15, 2021
Press Releases
CAMP4 Raises $45 Million to Usher in a New Era of Programmable Therapeutics to Upregulate Genes
October 29, 2019
Press Releases
CAMP4 Therapeutics Expands Board of Directors with Appointment of Steven Holtzman as Chair and Dr. Paula Ragan as Director
1
2
»
Media Contact:
PR@camp4tx.com
Top
